Michael Carson - Jan 3, 2023 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role
Vice President, Finance
Signature
/s/ Michael Carson
Stock symbol
NVCT
Transactions as of
Jan 3, 2023
Transactions value $
-$22,478
Form type
4
Date filed
11/8/2024, 03:59 PM
Previous filing
Mar 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCT Common Stock Award $0 +28.8K +105.52% $0.00 56.1K Jan 3, 2023 Direct F1, F2
transaction NVCT Common Stock Award $0 +34.6K +61.61% $0.00 90.7K Jan 4, 2024 Direct F2, F3
transaction NVCT Common Stock Sale -$22.5K -2.76K -3.04% $8.16 87.9K Nov 7, 2024 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The 28,806 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates.
F2 Includes shares of restricted common stock, which vest over various time periods.
F3 The 34,567 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates.
F4 In connection with the vesting of 9,100 shares, 2,755 shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Carson's tax withholding obligations. Mr. Carson had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.